Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Recs

1
Player Avatar TMFBiologyFool (98.28) Submitted: 10/13/2008 5:43:44 PM : Outperform Start Price: $5.14 ARRY Score: -62.12

Good pipeline. Market is overrating the risk.

Featured Broker Partners


Advertisement